NWPF

News ArchivesRead News

Your Parkinson's News Update for the Week of 2.1.21

Monday February 01, 2021
Organs-on-a-Chip Device Connects
Gut Microbiome with Parkinson’s
Science Advances via GEN News
"To help researchers better understand how this gut-brain axis communicates, Massachusetts Institute of Technology (MIT) researchers have developed an “organs-on-a-chip” system that replicates interactions between the brain, liver, and colon.
Using their system, the researchers were able to model the influence that gut microbiome organisms have on both healthy brain tissue and tissue samples derived from patients with Parkinson’s...'It seems that short-chain fatty acids can be linked to neurodegenerative diseases by affecting lipid metabolism rather than directly affecting a certain immune cell population,' researcher Trapecar said. 'Now the goal for us is to try to understand this.'”
High Interest in Medical Cannabis
as Parkinson’s Treatment, Survey Says
Journal of Parkinson's Disease via Parkinson's News Today
"Despite scant clinical data, interest in possible medicinal uses of cannabis — often known best for THC, its main psychoactive ingredient — has grown alongside the compound’s increasing global legalization.
Cannabis has found use worldwide as a treatment for the symptoms of several diseases, including Parkinson’s, and for other illnesses.
'There are few data about which type of cannabinoid and which route of administration might be promising for which [Parkinson’s] patient and which symptoms,' Carsten Buhmann, MD, of the department of neurology at the University Medical Center Hamburg-Eppendorf and the study’s senior author, said in a press release."
Prostate Drug Associated with Lower Risk of Parkinson's
JAMA Neurology via Parkinson's News Today
"Taking a particular type of medication to treat enlarged prostate is associated with a reduced risk of developing Parkinson's disease, according to a large observational study led by researchers at the University of Iowa, with colleagues in Denmark and China.
'Despite the relative differences in population and health care system structure, we found a similar protective effect in both countries," researcher Simmering notes. 'The replication of the finding in an international cohort is powerful evidence suggesting a causal effect. If these results are confirmed through further investigation, especially a randomized clinical trial, terazosin may provide neuroprotection and potentially prevent—and not just manage—Parkinson's.'"